Kintara Therapeutics, a biopharmaceutical company based in San Diego, develops new cancer therapies, including the late-stage REM-001 for cutaneous metastatic breast cancer and VAL-083 for drug-resistant solid tumors. The company went public on July 12, 2016, and has two employees.
TuHURA Biosciences (HURA) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, TuHURA Biosciences's actual EPS was -$1.37, missing the estimate of -$0.10 per share, resulting in a -1243.14% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
